Who
Atul Pande
Director
Company insider
Files Form 4 as: Director, Immunovant; Director, Karuna Therapeutics; Director, Sio Gene Therapies.
In numbers
- Trades disclosed
- 139
- Buys
- 6
- Sells
- 28
- Bought
- $210K
- Sold
- $9.1M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 29 Apr 2016
- Last trade
- 28 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Aug 2026filed 28 Aug 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $13K1,500 at $8.43 | filing |
| 28 Aug 2026filed 28 Aug 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $65K1,500 at $43.27 | filing |
| 28 Aug 2026filed 28 Aug 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 28 Aug 2026filed 28 Aug 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 28 Aug 2026filed 28 Aug 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $13K1,500 at $8.43 | filing |
| 28 Aug 2026filed 28 Aug 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $65K1,500 at $43.27 | filing |
| 24 Jul 2026filed 24 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $13K1,500 at $8.43 | filing |
| 24 Jul 2026filed 24 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $60K1,500 at $39.80 | filing |
| 24 Jul 2026filed 24 Jul 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 24 Jul 2026filed 24 Jul 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 24 Jul 2026filed 24 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $13K1,500 at $8.43 | filing |
| 24 Jul 2026filed 24 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $60K1,500 at $39.80 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $13K1,500 at $8.43 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $57K1,500 at $38.01 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $13K1,500 at $8.43 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $57K1,500 at $38.01 | filing |
| 15 Jun 2026filed 16 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $13K1,500 at $8.43 | filing |
| 15 Jun 2026filed 16 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $51K1,500 at $34.02 | filing |
News
Director Atul Pandey on National Award win for 'Main Nida': Hopelessly surrealhindustantimes.com · 23 Sep 2026
1 headline in the last 90 days name Atul Pande; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.